Valproate to Help Residual Amblyopia in Kids 8-17
Official title: Valproate for the Treatment of Residual Amblyopia
Run by Boston Children's Hospital · NCT07226141 · Data updated 2026-11-12
This trial tests whether adding valproate to standard patching can improve vision in children and teens with residual amblyopia beyond the normal treatment window.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 8 Years to 17 Years |
| Sex | All |
| Enrollment | 28 (estimated) |
| Sponsor | Boston Children's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | September 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT07226141 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents aged 8-17 with residual unilateral amblyopia related to strabismus and/or anisometropia, who are currently or recently undergoing patching therapy and meet specific visual acuity criteria.
✕Probably not a fit
Patients whose amblyopia does not respond to HDAC inhibition or who experience adverse effects from valproate may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot, randomized, double-blind, placebo-controlled study evaluates valproate as an adjunct to patching for residual amblyopia in 8-17-year-olds. Participants with unilateral amblyopia due to strabismus and/or anisometropia and a history of stable reduced vision will receive daily patching plus either valproate or placebo for 16 weeks. Valproate is hypothesized to enhance neural plasticity and support durable visual gains when combined with standard therapy. The trial includes safety monitoring to assess tolerability of valproate in this population. The study is conducted at Boston Children's Hospital, led by a pediatric research team.
Why it matters
Potential benefit: If successful, the approach could provide additional vision improvement for children and adolescents with residual amblyopia who have not fully recovered with standard treatment.
How similar studies have gone: Prior translational work suggests valproate can enhance plasticity and reopen critical-period-like mechanisms, but human studies in amblyopia are investigational and early.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age 8-17 years
2. Amblyopia associated with strabismus and/or anisometropia
* Criteria for strabismus: must meet at least one of the following:
* Heterotropia at distance and/or near with or without spectacle correction
* History of strabismus surgery
* Documented history of strabismus that is no longer present and felt by the investigator could have caused the amblyopia
* Criteria for anisometropia: must meet at least one of the following:
* ≥ 0.50 D difference in spherical equivalent between eyes
* ≥ 1.50 D difference in astigmatism in any meridian between the eyes
3. Visual acuity measured in each eye within 7 days prior to enrollment using ETDRS protocol on a study certified visual acuity tester as follows:
* Amblyopic eye visual acuity of 20/40 - 20/400
* Sound eye acuity of ≥ 20/25.
4. Current amblyopia treatment (other than spectacle correction)
* Subjects actively patching at the time of enrollment screening should continue patching through enrollment
* Visual acuity in amblyopic eye has not improved ≥ 1 line (5 letters) by the same testing method from a previous visit ≥ 8 weeks earlier while on treatment
* Since this determination is a pre-study examination, the method of visual acuity testing is not mandated
* Atropine treatment at any time during this pre-enrollment period is not allowed
* Any treatment prior to the current patching episode with stable acuity is allowed
5. Spectacle correction for measurement of enrollment visual acuity must meet the following criteria and be based on a cycloplegic refraction \< 6 months old:
• Requirement for spectacle correction:
* Spherical equivalent must be within 0.50 D of fully correcting anisometropia
* Hyperopia ≥ 3.00 D must be corrected
* Hyperopia may not be undercorrected by \> 1.50 D spherical equivalent and must be symmetrically reduced in each eye
* Cylinder power must be within 0.50 D of fully correcting the astigmatism
* Cylinder axis must be within 6 degrees of the axis in the spectacles when the cylinder power is ≥ 1.00 D
* Myopia of the amblyopic eye \> 0.50 D spherical equivalent must be corrected
◊ Myopia may not be undercorrected by \> 0.25 D or overcorrected by \> 0.50D
• Spectacles meeting the above criteria must be worn:
* Until visual acuity in amblyopic eye has not improved ≥ 1 line (5 letters) by the same testing method during 2 consecutive visual acuity measurements at least 4 weeks apart (i.e. minimum of 8 weeks spectacle correction) ◊ Since this determination is a pre-study examination, the method of visual acuity testing is not mandated
6. Eye examination within 6 months prior to enrollment
7. Subject must be available for at least 6 months of follow-up, have access to a phone, and be willing to be contacted by clinical staff
8. By investigator judgment, the subject is likely to comply with prescribed treatment (i.e. no prior history of poor compliance with patching) and unlikely to continue to improve with 2 hours of daily patching alone
2.2.2 Exclusions
1. Myopia \> -6.00 D spherical equivalent
2. Presence of associated findings that could cause reduced visual acuity
• Nystagmus does not exclude the subject if the above visual acuity criteria are met
3. Previous intraocular or refractive surgery
4. Strabismus surgery planned within 16 weeks
5. Current vision therapy or orthoptics
6. Known past or present liver or kidney disease
7. Known past or present mitochondrial/metabolic disorder
8. Known past or present psychological problems
9. Known allergies or contraindications to the use of valproate or anti-epileptic medication
10. Current use of medication for the treatment of seizures, bipolar disorder, or migraine, or any medication on the appended list of medications that interact with valproate/valproate acid and its derivatives which can be found here.
11. Prior valproate use
12. Known skin reaction to patch or bandage adhesives
13. Treatment with topical atropine within the past 12 weeks
14. Individuals capable of pregnancy who are pregnant, lactating, or may become pregnant within the next 6 months
* A negative urine pregnancy test will be required for all participants who have experienced menarche at the time of enrollment
* Individuals capable of pregnancy must convey an active suitable plan to avoid pregnancy that includes at least one of the following:
* Hormonal Contraceptives:
* Combined oral contraceptives (the pill)
* Contraceptive patch
* Vaginal contraceptive ring
* Progestin-only pills
* Hormonal injections (e.g., Depo-Provera)
* Hormonal implants (e.g., Nexplanon)
* Intrauterine Devices (IUDs):
* Copper IUD (e.g., ParaGard)
* Hormonal IUDs (e.g., Mirena, Skyla, Liletta)
* Barrier Methods with Spermicide (less commonly used alone but may be used in combination with other methods for added protection):
* Male condoms
* Female condoms
* Diaphragms with spermicide
* Cervical caps with spermicide
* Sterilization:
* Tubal ligation (for females)
* Vasectomy (Having a partner who has undergone a vasectomy, confirmed by semen analysis)
* Abstinence or True Sexual Abstinence:
o Refraining from heterosexual intercourse
* Requirements regarding the establishment of pregnancy status and monitoring for pregnancy over the course of the study may be further defined by the IRB
Where it's running
-
Boston Children's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Eric D Gaier, MD, PhD — Boston Children's Hospital
- Study coordinator: Eric D Gaier, MD, PhD
- Email: Eric.Gaier@childrens.harvard.edu
- Phone: 617-355-6401
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
tDCS for paediatric amblyopia
This study tests whether non-invasive brain stimulation (tDCS) can improve vision for children aged 4–14 with amblyopia who didn’t get enough help from patching.
-
Psilocybin-assisted therapy to help adults with amblyopia see more clearly
This study tests whether a single or small doses of psilocybin can boost the effectiveness of amblyopia treatment in adults.
-
Augmented Reality Binocular Therapy for Adult Amblyopia
This trial tests a home-based augmented reality binocular therapy to see if it improves vision in adults 18–40 with anisometropic amblyopia, compared with placebo training.
-
Gabor-based visual training for adults with amblyopia
This study tests a computer-based Gabor training program to see if it can improve vision in adults aged 18–39 with amblyopia due to anisometropia or strabismus.
-
Noninvasive brain stimulation plus augmented reality vision therapy for anisometropic amblyopia in adults
This trial tests whether adding HD-tDCS to AR-based dichoptic therapy can improve vision in adults with anisometropic amblyopia.
-
Gamified visual training with occlusion for kids with anisometropic amblyopia
This trial tests two kid-friendly digital games plus patching to see if they improve vision and motivation in children aged 4–7 with anisometropic amblyopia compared with patching alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.